002393.SZTianjin Lisheng Pharmaceutical Co.,Ltd.
Oct 28, 2026 — Q3 2026 Earnings Release
Chart by TradingViewThe schedule
- Wed28Oct
- Fri20Nov
Key domestic bidding results for bulk generic drug procurement will determine production volumes and guaranteed market share for the upcoming fiscal year.
- Tue20Apr
Full-year 2026 results and crucial board decisions regarding dividend payouts or share buybacks utilizing the company's significant net cash position.
- Tue15Jun
Expected regulatory decisions from the National Medical Products Administration (NMPA) on new specialty generic applications submitted in 2026.
Resolved
- Fri21Aug
MIXED · $14.30 at outcome
Price at outcome date was between bear floor ($13.50) and bull target ($15.50).
Expected announcement of H1 2026 results. The focus is on stemming the -10.16% YoY revenue contraction and addressing the -$1.7M free cash flow drag from the latest quarter.